ProQR Therapeutics Announces Encouraging Phase 1 Trial Data for AX-0810.

ProQR Therapeutics reported initial data from its Phase 1 trial of AX-0810, showing no safety signals and pharmacokinetics consistent with non-clinical data. The company also announced the selection of development candidates for its pipeline programs AX-2402 for Rett syndrome and AX-2911 for MASH. Additionally, ProQR achieved $4.5 million in milestones from its strategic collaboration with Eli Lilly, contributing to its strong financial position with a runway into mid-2027.